Follows people with heart rhythm problems treated with catheter ablation
Records real-world results of catheter ablation for atrial fibrillation and ventricular arrhythmia in adults.
Key facts
- Who runs it
- Heart Rhythm Clinical and Research Solutions, LLC
- Where
- Edmonton, Kitchener, Montreal, and Newmarket, CanadaSee the 4 sitesAlso in 1 other country, 71 sites
- Trial code
- Registry title
- Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias
- Status
- Recruiting
- People taking part
- 20,000 people, planned
- Started
- 1 Jan 2018
- Expected to end
- 31 Dec 2028
- Type of study
- Observational, 2 groups
- Treatments tested
- Catheter ablation
- Record updated
- 22 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with atrial fibrillation (fast, irregular heartbeat) or ventricular arrhythmia who will have a catheter ablation with Biosense Webster Inc. technologies.
- Age
- Over 18 years
- Sex
- All
- Disease stage
- Atrial fibrillation cohort: symptomatic paroxysmal AF (episodes stop on their own within 7 days) or persistent AF (lasting beyond 7 days but less than 365 days). Ventricular arrhythmia cohort: documented ventricular arrhythmia appropriate for catheter ablation.
- Earlier treatment
- Repeat ablations are allowed in the AF cohort, including when the first procedure used a non-BWI catheter. Treatment must be with Biosense Webster Inc. ablation technologies.
Main reasons for not taking part
- Taking part in an investigational drug or device trial, or any trial that sets the treatment plan
- Long-standing persistent AF (AF longer than one year), in the AF cohort
- Any known reason the investigator judges to rule out an ablation procedure
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Symptomatic PAF (AF episode terminate spontaneously within 7 days) or PsAF (AF sustained beyond 7 days, but less than 365 days) subjects who, in the opinion of the investigator, are candidates for catheter ablation
- >18 years of age
- Will be treated with Biosense Webster Inc. ablation technologies
- All AF ablations performed with BWI catheters are included. This includes repeat ablations where the index procedure was performed with a non-BWI catheter
- Able and willing to participate in baseline and follow up evaluations
- Willing and able to provide informed consent, if applicable
- Documented ventricular arrhythmia appropriate for catheter ablation
- >18 years of age
- Will be treated with Biosense Webster Inc. ablation technologies
- Able and willing to participate in baseline and follow up evaluations
- Willing and able to provide informed consent, if applicable
Who cannot take part
- Enrolled in an investigational drug or device clinical trial, or any trial that dictates the treatment plan
- Enrolled in an investigational drug or device clinical trial, or any trial that dictates the treatment plan
- Long-standing persistent AF (AF greater than one year)
- In the opinion of the investigator, any known contraindication to an ablation procedure; CORE VA Cohort
- In the opinion of the investigator, any known contraindication to an ablation procedure
Other criteria
- REAL AF Cohort
Where in Canada
Also in 1 other country, 71 sites
- Alberta HealthEdmonton, CanadaContact: Wei ChenTaking people
- Waterloo Wellington Cardiovascular Research InstituteKitchener, CanadaContact: Mary RadykTaking people
- Montreal Heart InstituteMontreal, CanadaContact: Caroline GirardTaking people
- Southlake Regional Health CentreNewmarket, CanadaContact: Lynn NymanTaking people
About the trial
What the trial wants to find out
The primary purpose of this Registry is to assess procedural safety and long-term effectiveness of catheter ablations in the treatment of subjects with PAF, PsAF, and VA. The Registry will utilize real world clinical data obtained from the use of commercially available CARTO™ technologies under the authority of a health care practitioner within a legitimate practitioner-subject relationship. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term effectiveness of catheter ablation with novel technologies for arrhythmia patients.
The 2 groups in the trial
- REAL AF
Subjects with symptomatic PAF or PsAF who, in the opinion of the investigator, are candidates for ablation for AF, age 18 years or older, and are able and willing to comply with all pre-, post-, and follow-up testing and requirements.
Treatment: Catheter ablation
- CORE VA
Subjects with documented ventricular arrhythmia appropriate for catheter ablation, greater than 18 years of age, will be treated with Biosense Webster Inc. ablation technologies, and are willing and able to participate in baseline and follow up evaluations.
Treatment: Catheter ablation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias Symptomatic Using Novel CARTO Technologies: REAL Registry
- Plain-language title
- Follows people with heart rhythm problems treated with catheter ablationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 22 September 2026